About Tethis
Tethis is a company based in Milan (Italy) founded in 2004. It operates as a HealthTech. Tethis has raised $15.33 million across 5 funding rounds from investors including European Union, ENEA Tech e Biomedical and unknown. Tethis offers products and services including Liquid Biopsy Solution. Tethis operates in a competitive market with competitors including GRAIL, Color, Biological Dynamics, Earli and Biovica, among others.
- Headquarter Milan, Italy
-
Sectors
TechnologyHealthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Tethis S.P.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.33 M (USD)
in 5 rounds
-
Latest Funding Round
$15.33 M (USD), Private Equity Round
Jan 14, 2025
-
Investors
European Union
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Tethis
Tethis offers a comprehensive portfolio of products and services, including Liquid Biopsy Solution.
Liquid biopsy is developed for early cancer detection.
Funding Insights of Tethis
Tethis has successfully raised a total of $15.33M across 5 strategic funding rounds. The most recent funding activity was a Private Equity Round of $15.33 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Tethis
Tethis has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, ENEA Tech e Biomedical and unknown.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Tethis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Tethis
Investment portfolio details for Tethis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Tethis
Detailed financials for Tethis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tethis Comparisons
Peer comparison for Tethis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Tethis
Tethis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GRAIL, Color, Biological Dynamics, Earli and Biovica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Circulating tumor DNA is screened for early cancer detection.
|
|
| Locked | Locked | Locked |
Cancer care is delivered through a virtual clinic by Color.
|
|
| Locked | Locked | Locked |
Proprietary lab-on-chip platform for nanoparticle isolation is offered.
|
|
| Locked | Locked | Locked |
Early cancer detection tests are developed using synthetic biomarkers.
|
|
| Locked | Locked | Locked |
Tumor response to cancer therapies is monitored via specialized assays.
|
|
| Locked | Locked | Locked |
Developer of nucleic acid detection and quantification systems
|
Detailed competitors of Tethis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tethis
Complete news archive for Tethis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tethis
Tethis was founded in 2004 and raised its 1st funding round 6 years after it was founded.
Tethis is headquartered in Milan, Italy. It is registered at Milan, Lombardy, Italy.
Tethis is a funded company, having raised a total of $15.33M across 5 funding rounds to date.
Tethis is engaged in the development of liquid biopsy solutions for early cancer detection and improved treatment guidance. The company operates in the healthcare sector, specifically targeting oncology diagnostics. Innovative approaches are utilized to preserve sample integrity through automated and standardized processing. Collaborations with institutions like Sheba Medical Center and Weill Cornell Medicine are maintained to enhance AI-powered diagnostics and cellular residual disease monitoring in cancers such as rectal and early-stage breast cancer.
Tethis offers Liquid Biopsy Solution.
Tethis has 4 investors. Key investors include European Union, ENEA Tech e Biomedical, unknown, and EIC Fund.